Fennec Pharmaceuticals Inc.
FENC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $48 | $21 | $1 | $0 |
| % Growth | 123.7% | 1,341.6% | – | – |
| Cost of Goods Sold | $3 | $1 | $0 | $0 |
| Gross Profit | $44 | $20 | $1 | $0 |
| % Margin | 93.3% | 94.1% | 94.4% | – |
| R&D Expenses | $0 | $0 | $3 | $5 |
| G&A Expenses | $23 | $21 | $0 | $0 |
| SG&A Expenses | $41 | $33 | $20 | $12 |
| Sales & Mktg Exp. | $18 | $12 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $42 | $33 | $23 | $17 |
| Operating Income | $3 | -$13 | -$22 | -$17 |
| % Margin | 5.4% | -60.1% | -1,471.6% | – |
| Other Income/Exp. Net | -$3 | -$3 | -$1 | -$0 |
| Pre-Tax Income | -$0 | -$16 | -$23 | -$17 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$16 | -$23 | -$17 |
| % Margin | -0.9% | -75.5% | -1,544.9% | – |
| EPS | -0.016 | -0.6 | -0.95 | -0.67 |
| % Growth | 97.3% | 36.8% | -41.8% | – |
| EPS Diluted | -0.016 | -0.6 | -0.95 | -0.67 |
| Weighted Avg Shares Out | 27 | 27 | 26 | 26 |
| Weighted Avg Shares Out Dil | 27 | 27 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $0 |
| Interest Expense | $4 | $3 | $1 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | $5 | -$12 | -$22 | -$17 |
| % Margin | 10.1% | -58.2% | -1,471.5% | – |